title: Current adoptive immunotherapy in non-small cell lung cancer and potential influence of therapy outcome.
abstract: Non-small cell lung cancer (NSCLC) is found worldwide with high incidence and poor prognoses. Nowadays, insights in the interaction between tumors and immune system have led to the development of immunotherapy as a fundamentally new concept for the treatment of NSCLC. Adoptive cell transfer represents an important advancement in cancer immunotherapy such as cytokine-induced killer and γδ T-cells. Recent clinical research studies provide evidence for the positive effects of adoptive immunotherapy, which is probably associated with levels of cytokines, cell doses, and immune microenvironment. This review summarizes the current condition of adoptive immunotherapy in NSCLC and the long-standing confusion in this field.
authors.affiliation: Department of Biotherapy, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
authors.forename: Ya-Wen
authors.initials: YW
authors.lastname: Zheng
authors.forename: Run-Mei
authors.initials: RM
authors.lastname: Li
authors.forename: Xin-Wei
authors.initials: XW
authors.lastname: Zhang
authors.forename: Xiu-Bao
authors.initials: XB
authors.lastname: Ren
mesh_terms: D002289:Carcinoma, Non-Small-Cell Lung / Q000276:immunology / Q000401:mortality / Q000628:therapy*; D006801:Humans; D016219:Immunotherapy, Adoptive / Q000379:methods*; D008175:Lung Neoplasms / Q000276:immunology / Q000401:mortality / Q000628:therapy*; D016896:Treatment Outcome